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Background
Antibacterial resistance is problematic and continues to increase despite
efforts to halt its expansion. Antibacterials have been used to treat
infectious diseases over the last 70 years. The long-term and improper
use of antibacterials has caused bacteria to develop resistance to
specific drugs and sometimes entire drug classes. 1 Staphylococcus
ACPE Universal Activity Number (UAN): 0048-0000-11-026-H01-P
aureus (S. aureus) is a gram-positive coccus that is part of the normal
skin flora and is prevalent in the environment. Staphylococcus infections
Objectives:
normally occur due to compromised host defenses and can cause a
After completion of this program, the reader should be able to:
variety of clinical syndromes with varying severity and symptomatology
in both community and hospital settings. 1 Normally, S. aureus would be
1. Define the types of MRSA
susceptible to the beta-lactam class of antibiotics with methicillin as the
2. List the medications that can be used to treat CA-MRSA
original treatment of choice for Staphylococcus infections. The beta3. List the medications that can be used to treat HA-MRSA
lactam antibiotics exert their antibacterial action by binding to penicillin4. Identify how MRSA can be transmitted in the community and health binding proteins (PBPs) located in bacterial cell walls, inhibiting cell wall
care settings
biosynthesis and ultimately causing cell lysis and death. 2 However, S.
5. Distinguish the importance of evidence-based medicine and pubaureus has grown resistant to methicillin treatment by a mechanism
lished guidelines in helping with antibacterial resistance
decreasing binding of beta-lactams to PBPs. Methicillin-resistant Staphy6. State the preferred treatments of MRSA in certain clinical syndromes lococcus aureus (MRSA) produces a different PBP known as PBP2a,
binding beta-lactam antibiotics with much less affinity than PBP. PBP2a
is encoded by mecA gene, which is contained in the Staphylococcal
cassette
chromosome (SCC). Currently, at least five types of sec are
Abstract
As of February 2011, the Infectious Disease Society of America
known (1-V), and mecA IV has four subtypes (a-d), which are all used to
(IDSA) published the first guidelines assessing the treatment of
classify MRSA strains. 3
methicillin-resistant Staphylococcus aureus (MRSA} infections. S.
Community-acquired MRSA (CA-MRSA) is normally type IV or V, and
aureus is present in the environment and is also located on the
more virulent than hospital-acquired MRSA (HA-MRSA}. CA-MRSA
skin's surface. MRSA can cause a variety of clinical syndromes presenting with different symptoms that vary with the type and stage
most commonly presents as a skin infection and is usually spread
of the infection. MRSA is also classified into community-acquired
through contact with another person's skin infection or personal items
MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA), both
that have been contaminated, such as towels, razors or bandages. This
of which possess different treatment options and strategies. Due
transmission usually occurs through close skin-to-skin contact or open
to the complex treatment of MRSA, as well as the concern over
skin wounds, such as abrasions or cuts. With these conditions, locations
the development of resistance, suggested treatment guidelines are
where people are in close contact (athletic facilities, dormitories, daycare
critical for improvement in clinical outcomes. The recently pubcenters and correctional facilities) are at higher risk for infection spread.
lished IDSA guidelines come in lieu of those previously published
CA-MRSA is susceptible to a variety of non-beta-lactam antibiotics and
in 2006 by the UK The U.S. publication was most likely prompted
has more treatment options.
due to an article published in The Journal of the American Medical
Association (JAMA) suggesting MRSA was twice as common as
In contrast, HA-MRSA is typically more resistant because the sec types
other invasive infections and correlated with significant mortality.
I, II, and Ill in the strains common to this setting can carry resistance
Although the publication of new evidence-based guidelines for the
genes. In the health care setting, MRSA is most commonly transmitted
treatment of MRSA will most likely result in improved therapeutic
through unclean hands of personnel or improper use of equipment and
outcomes, it is pertinent that health care providers receive adequate
devices. Appropriate hand-washing with hot soap and water or using an
education regardlng the use of the guidelines.
alcohol-based hand sanitizer, as well as appropriate isolation procedures with infected individuals, can help prevent the spread of MRSA.
Due to the prevalence of multidrug resistance of types I, II, and Ill common to HA-MRSA, this type has fewer treatment options.

This knowledge-based activity is targeted for all pharmacists and is
acceptable for 1.0 hour (0.1 CEU) of continuing education credit. This
course requires completion of the program evaluation and at least a
I 70 percent grade on the program assessment questions.
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CA-MRSA Treatment Options
CA-MRSA most commonly presents as skin and soft tissue infections (SSTis) clinically ranging from impetigo to life-threatening necrotizing fasciitis. 4
This is associated with a cytotoxin, Panton-Valentine leukocidin (PVL),
which causes cell lysis of the human leukocytes. PVL is also related to
nectrotizing pneumonia and sepsis, although these severe conditions occur infrequently.3 The primary treatment of abscesses is surgical drainage,
but antibiotic therapy is recommended with certain conditions. The treatment duration is five-10 days but should be individualized based on the
patient's clinical response. 5 Oral drug therapy options include the following:
sulfamethoxazole/trimethoprim (SMX!TMP) one to two double-strength
tablets twice daily to three times daily, clindamycin 300-450 mg three times
daily, doxycycline 100 mg twice daily, linezolid 600 mg every 12 hours. 5•6
Potential clindamycin resistance exists, and a double-disc diffusion assay
"D-tesf' should be performed to determine macrolide-lincosamide-streptogramin type B (MLS8) inducible resistance.5

most common side effects are nausea, vomiting and diarrhea. An advantage to using this medication is that it is not renally adjusted. 6
Vancomycin (Vancocin®)
Vancomycin is a glycopeptide antibiotic that has been the drug of choice
for MRSA and has been used since the 1950s. Efficacy is related to the
area under the curve (AUC) and the minimal inhibitory concentration (MIC).
Patient weight, renal function and the severity of the disease affect dosing
requirements.7 Some experts use combination therapy with rifampin and
gentamicin for synergy, especially for more serious infections such as prosthetic valve endocarditis. Normal adult dosing is usually between 15-20 mg/
kg/dose every eight to 12 hours, with treatment duration depending on the
clinical syndrome. Initial doses are based on actual body weight, and serum
trough levels should help determine the subsequent doses. Rapid intravenous administration may cause a reaction known as "Red Man's Syndrome,"
which is characterized by hypotension and a rash of the upper body.6

Guidelines
In 2004, Wessex microbiologists reviewed the management of MRSA and
survival rates of patients with a MRSA infection in participating British hospitals.8Between March 1995 and December 2003, only 64 percent of patients
with MRSA lived longer than 28 days, which was considered unacceptable
and spurred the National Institute for Health and Clinical Excellence (NICE)
to create guidelines on the management of MRSA. 8In 2006, a joint Working
Party of the British Society for Antimicrobial Chemotherapy published new
guidelines that focused on the prophylaxis and treatment of MRSA infections
in the U.K.9 The first U.S. guidelines were published five years after those
in the U.K., but the Infectious Diseases Society of America (IDSA) did not
provide a direct explanation for their need. It is possible the guidelines published by the IDSA were prompted by an article published by The Journal of
the American Medical Association (JAMA) in October 2007, which assessed
the incidence of invasive MRSA in 2005. The standardized incidence rate
was revealed to be 31.8 per 100,000 persons. 1°Compared to other invasive
infections such as S. pneumoniae or H. influenzae, MRSA was twice as
common and associated with increased mortality. 10 Ideally, the implementation of the recently published U.S. guidelines will result in reduced drug
resistance and improved patient outcomes.

HA-MRSA Treatment Options
Although CA-MRSA also would be susceptible to these antibacterials,
these are not the recommended treatment options as a result of cost
and resistance concerns. On the contrary, the therapies for HA-MRSA
should never be used in CA-MRSA treatment strategies due to high
prevalence of resistance.
Daptomycin (Cubicin®)
Daptomycin is a lipopeptide class antibiotic that has FDA labeled and
unlabeled indications in the management of MRSA. The normal adult
dose is 4-6 mg/kg once daily for one to six weeks. 6 This medication
should not be used in MRSA presentations of pneumonia, as it is inactivated by lung surfactant. 5 Cases of eosinophilic pneumonia have been
reported, and it is recommended to discontinue daptomycin use if this
condition is suspected. 6
Linezolid (Zyvox®)
Linezolid is an oxazolidinone class antibiotic that has 100 percent oral
bioavailability and, therefore, should be used orally unless contraindicated.
Long-term use is limited by hematologic toxicity, so CBC should be checked
weekly. 5 The normal dose is 600 mg every 12 hours for two to eight weeks. 6

Table 1. U.K. Practice Guidelines Strength of Evidence Categories9•11
Rifampin
Because of resistance, rifampin is not used as monotherapy to treat
MRSA. It has been used as synergy in some situations, although its
definitive role as adjunctive therapy has not been established. 5

Category

Definition

IA

Strongly recommended for implementation and strongly
supported by well-designed experimental, clinical or
epidemiological studies

Telavancin (Vibativ®)
This lipoglycopeptide is active against MRSA as well as vancomycinintermediate S. aureus (VISA) and vancomycin resistant S. aureus
(VRSA). 5 It is approved for SSTls with a normal adult dose of 10 mg/kg
IV every 24 hours for one to two weeks. 6 Renal adjustments are needed,
and nephrotoxicity is a concern with its use. 5

IB

Strongly recommended for implementation and supported by certain experimental, clinical or epidemiological studies and a strong theoretical rationale

IC

Required for implementation as mandated by federal or
state regulation or standard or representing an established association standard

II

Suggested for implementation and supported by
suggestive (non-definitive) clinical or epidemiological
studies or a theoretical rationale

Unresolved
issue

No recommendation is offered. No consensus reached,
or insufficient evidence exists regarding efficacy.

Tigecycline (Tygacit®)
A derivative of tetracyclines, tigecycline has activity against grampositive and gram-negative organisms, including MRSA. It can only be
administered intravenously, with an initial dose of 100 mg followed by a
maintenance dose of 50 mg every 12 hours for seven to 14 days. The
5

The Pharmacy and Wellness Review

Volume two, Issue two

May 2011

Will New MRSA Guidelines Make a Difference in Clinical Outcomes?
A Comparison of United States and United Kingdom Guidelines and Outcomes
New evidence emerged shortly after the release of the first guidelines
(2006), which fueled new recommendations, and an update was
published in March 2009. 11 The initial guidelines did not provide any
recommendations for treatment of impetigo and boils, but the update
included a category II recommendation to treat impetigo due to MRSA
with topical mupirocin or fusidic acid, if susceptible, and to not use antibiotics for small boils. The updated version also differentiates between
treatment for hospitalized and non-hospitalized patients with cellulitis
or surgical site infections, including step-therapy based on antibiotic
susceptibility. The recommendation to use rifampin in addition to fusidic
acid to treat SSTls was removed due to adverse effects and newer,
less-toxic options such as daptomycin and tigecycline. Clindamycin was
designated as the antibiotic of choice, and the new guidelines emphasize the importance of patient education on diarrhea due to clindamycin-associated C. difficile. First-line treatment options for uncomplicated
urinary tract infections (UTls) due to MRSA now include oral nitrofurantoin, trimethoprim, SMX/TMP in addition to tetracycline based on in vitro
susceptibility. Complicated UTls should be treated with a glycopeptide
or daptomycin. When treating bacteremia and endocarditis, the previous category IA recommendation of 14-day minimum treatment with a
glycopeptide or linezolid for uncomplicated cases and longer treatment
periods for high-risk patients remains, although it is now a category II
recommendation with daptomycin also recognized as an alternative
treatment option. The initial guidelines provided a category II suggestion
to use non-glycopeptide agents to treat bronchiectasis without pneumonia, but upon review of current evidence, this is considered an unresolved issue, with linezolid as a preferred treatment option due to better
penetration into lung tissue (category IC). The recommendation remains
to use glycopeptides or linezolid for lower respiratory tract infections
due to MRSA. Fucidic acid has been added as an appropriate option to
treat susceptible superficial eye infections.
Table 2. IDSA Practice Guidelines Strength of Evidence Categories5
Category/grade
A

B

c
I

II

Ill

Definition
Good evidence to support a recommendation for
or against use
Moderate evidence to support a recommendation for or against use
Poor evidence to support a recommendation
Evidence from ::::1 properly randomized, controlled trial
Evidence from ::::1 well-designed clinical trial
without randomization; from cohort or casecontrolled analytic studies (preferably from
>1 center); from multiple time series; or from
dramatic results from uncontrolled experiments
Evidence from opinions of respected authorities,
based on clinical experience, descriptive studies, or reports of expert committees

As of February 2011, the Infectious Diseases Society of America (IDSA)
has published the first evidence-based medicine (EBM) U.S. guidelines
for the treatment of MRSA. The guideline was formulated by an expert
panel in the area of infectious disease as it pertains to MRSA. 5 The

Infectious Disease

objective of this new guideline is to provide recommendations on the
management of some of the most common clinical syndromes encountered by adult and pediatric clinicians who care for patients with MRSA
infections. 5 The guideline also addresses several issues pertaining to
treatment of MRSA with vancomycin, such as dosing, monitoring and
problems regarding susceptibility testing. This guideline specifically
states it does not address the issues of surveillance or MRSA-prevention
strategies. Several clinical questions pertaining to different clinical syndromes, such as SSTls, bacteremia, endocarditis, pneumonia, bone and
joint infections and CNS infections associated with MRSA, are answered
within this guideline. Table 3 summarizes the three sets of guidelines
and each of the recommendations made for each clinical syndrome. The
recommendations listed are those that received the highest evidence
grade for each respective syndrome.
Evidence Based Medicine (EBM)
EBM is grounded in the idea of creating a method to effectively rank evidence according to its statistical strength and the accuracy of results. 12
In most cases, EBM relies on a grading system to assess the characteristics of the methods utilized to conduct the evidence-gathering process
and subsequent analysis of this gathered evidence. EBM takes into
consideration study type, randomization, blinding, selection of subjects
and controls, and all of the procedures associated with these events.
With the ranking system EBM utilizes, evidence can be adequately assessed for strength and quality and, therefore, can be applied appropriately to therapeutic decision-making. Without the use of EBM, evidence
with inadequate or potentially inaccurate conclusions has the potential
to be applied and, hence, result in the generation of poor or suboptimal
therapeutic outcomes. Within the 2011 IDSA guidelines, evidence was
graded according to the quality of evidence (Table 2). These grades
were then used to generate strength of recommendation. Strengths were
A, B and C conveying good, moderate and poor evidence to support a
recommendation, respectively. It is pertinent to note the IDSA guidelines
follow evidence-based medicine practices when it comes to evaluating
the evidence and, therefore, have the potential to influence health outcomes positively. Within the clinical guideline summary, only the highest
recommendations were listed, as there are many different treatment
options available.
Importance of and Adherence to Guidelines
The new U.K. guidelines did not prove to decrease mortality rates, according to a retrospective study completed in January 2009, three years
after the initial guidelines were published. 8 Data for 1,679 patients from
seven hospitals was divided into three groups based on the collection date of a positive MRSA blood culture. Group A included patients
through 2003 (when it was decided to create the guidelines), group
8 included patients from 2004 and 2005 (during the formation of the
guidelines), and group C included patients from 2006 to 2008 (after
publication of the guidelines). Physicians were 96 percent compliant
with the guidelines. Survival rates of the different groups did not differ,
but the number of MRSA bacteremias decreased from 300 in 2004 to
111 in 2008. This suggests that, although the guidelines did not improve
survival rates, they were effective in decreasing the number of infections
per year. The study also showed an inverse relationship between survival rates and age of the patient, implying survival rates may be more
dependent on patients' co-morbidities than MRSA.
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Table 3. Summary and Comparison of U.K. and U.S. Guidelines 5•9•11

2006 U.K. guidelines

2008 U.K. guideline update

2011 U.S. ISDA guidelines +strength
of evidence

No recommendation

Topical mupirocin or fusidic acid
(unless small and not surrounded
by cellulitis)

Simple abcesses/boils: incision and
drainage (All)

SSTis
Impetigo and
Boils

Doxycycline or clindamycin**

Purulent cellulitis: Clindamycin, SMX/
TMP, doxycycline, minocycline, linezolid
(All)

No change

Non-purulent cellulltis: '3-lactam,
clindamycin, linezolid (All)

Ulcers and Bolls
Cellulitls/Surgical Tetracyclines*
Site Infections
Glycopeptides or Linezolid**
IV infusion sites Severe: glycopeptides or
linezolid

Complicated: Vancomycin, linezolid
(Al/II)

Mild: other oral agents
Urinary Tract
Infections

Tetracyclines or alternatively Simple: oral trimethoprim,
trimethoprim or nitrofurantoin nitrofurantoin, or SMX/TMP or
tetracycline

n/a

Severe: glycopeptides or daptomycin
Bone and
Joint lnfections

Prosthetic joint
infection

No change

Osteomyelitis: Vancomycin (Bii/Aii)
Septic arthritis: Vancomycin (Bil/All)

Other

Bacteremia
and endocarditis

Vancomycin + rifampin or
vancomycin + fusidic acid

Uncomplicated
bacteremia

Rifampin + a fluoroquinolone No change
or trimethoprim or fusidic
acid
14 day minimum linezolid or No change
glycopeptides

Bacteremia/endocardltls/infective
endocarditls with native valve: vancomycin (Biii)

(linezolid limitation here)

Respiratory
tract infections

Eye and CNS
infections

Elimination
of carriage

Complicated
bacteremia or
endocarditis

Longer treatment

No change

Infective endocardltis with prosthetic
valve: vancomycin + gentamicin +
rifampin (Biii)

Upper Respiratory
Tract Infection

See cellulitis recommendations

Linezolid offers good penetration

n/a

Lower Respiratory
Tract Infection

Glycopeptides or linezolid

No change

Vancomycin, linezolid (All)

Insufficient evidence for
deep eye and CNS infections. Superficial infections:
gentamicin or chloramphenicol
Mupirocin in combination
with a systemic agent

Superficial infections: gentamicin
or chloramphenicol or fusidic acid

Vancomycin or linezolid {Bii)

No change

n/a

No change

n/a

Surgical site
Glycopeptides
infection
prophylaxis
..
*Unless there 1s a nsk of bacterem1a or endocard1t1s
**If the risk of bacteremia is high
7
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A questionnaire assessing health care workers' awareness of the MRSA
practice guidelines revealed an inadequate knowledge of current MRSA
practice guidelines in 2009, three years after they were released. 13 The
questionnaire contained 10 true-or-false questions, and the scores of
physicians (6.532) and trainee surgeons (6.904) were compared to
control groups of infectious control nurse practitioners (8.391) and nonclinical scientific staff (4.7). The results demonstrated room for significant improvement among physicians and trainee surgeons, although the
study had a few major limitations. The study did not randomly sample
the studied populations (physicians and surgeons surveyed attended a
medical conference), and there was no evaluation of random answers.
This study suggests health care workers must be thoroughly educated
for guidelines to be maximally effective.
Conclusion
Development of EBM guidelines has the potential to significantly impact
both CA-MRSA and HA-MRSA treatment strategies via the standardization of therapy based on graded clinical data. Education of health care
providers on the usage of the guidelines has the potential to change
the clinical outcomes of treatment of MRSA infection. With appropriate
education, inappropriate medication usage has the potential to decrease development of resistance, patient length of stay in the hospital,
and use of unnecessary treatment for the presenting syndrome. All of
these factors lead not only to improved patient quality of life, but also
to decreased health care costs. Overall, use of the guidelines has the
potential to impact a variety of clinical and economic factors supporting
its usage in the treatment of MRSA infection.

Infectious Disease
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9. The strongest level of evidence is associated with well-designed:
a. Professional opinions
b. Multiple meta-analysis
c. Randomized controlled trials
d. Cohort studies

Assessment Questions
1. S. aureus has become resistant to beta-lactams, such as methicillin,
due to:
a. Decreased binding to penicillin-binding proteins
b. Production of beta-lactamases
c. Increased activity of efflux pumps
d. Altered metabolic pathways

10. In order for the ISDA guidelines to be effective:
a. The guidelines should help determine treatment strategies
b. Health care workers must be knowledgeable
c. Health care works should be educated about MRSA transmission
d. All of the above

2. What type of SCC characterizes CA-MRSA?
a. I or II
b.11 or Ill
c.111 or IV
d. IV orV

Ohio Northern University is accredited by the Accreditation
Council for Pharmacy Education as a provider of continuing
pharmacy education. This program is eligible for credit until
, April 5, 2014.

3. All of the following are locations with a high-risk of CA-MRSA
transmission EXCEPT:
a. Correctional facilities
b. Daycare centers
c. Grocery stores
d. Athletic locker rooms

4. Which of the following is an option to treat CA-MRSA?
a. Vancomycin 1 g IV BID
b. Doxycycline 100 mg po BID
c. Oxacillin 2 g IV 06 hr
d. Linezolid 600 mg po BID
5. Which of the following IV medications is NOT an option to treat HAMRSA?
a. Vancomycin
b. Daptomycin
c. Telavancin
d. Ceftriaxone
6. The 2009 updated U.K. guidelines did not include the recommendation to use rifampin + fusidic acid to treat SSTls due to:
a. Adverse effects
b. Improved newer drug options
c. Increased resistance
d. A and B
7. The recently published ISDA guidelines for the U.S. suggests treating
simple abcesses/boils with:
a. Incision and drainage only
b. Incision and drainage with topical mupirocin
c. Vancomycin
d. Doxycycline
8. Recommendations backed by the strongest evidence is categorized as:
a. IA
b. IC
c. lllA
d. lllC
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